Abstract：【Objective】To investigate the efficacy and safety of pitavastatin in the treatment of hyperlipidemia with type 2 diabetes mellitus(T2DM) in elderly patients. 【Methods】A total of 83 elderly patients with hyperlipidemia and type 2 diabetes mellitus who admitted to 464 PLA Hospital from May 2016 to April 2019 were enrolled in the study. Lab examinations such as liver, renal and thyroid function were carried out , then the original statins were replaced by pitavastatin. The FPG(fasting glucose),2hPG(2 h postprandial blood glucose), HbAlC(glycosylated hemoglobin), TC and TG(triacylglycerol) levels were compared before and after treatment. 【Results】After treatment with Pravastatin, the levels of FPG, 2hPG, HbA1C, TG and mAlb(urine microalbumin) were further decreased(P<0.05), while CK(creatine kinase) , CKMB(creatine kinase isoenzyme), LDH(lactate dehydrogenase), BUN(urea nitrogen) , SCr(creatinine), ALT(alanine aminotransferase) and T3(triiodothyronine) did not change significantly, and no adverse reactions occurred during the treatment. 【Conclusion】Efficacy and safety of pitavastatin in elderly men with hyperlipidemia disease and type 2 diabetes mellitus were better. It is worthy of clinical popularization and application.
[1] 雷蕾, 张熙洋, 崔立芹, 等. 阿托伐他汀和瑞舒伐他汀对2型糖尿病血脂和高敏C反应蛋白作用效果的比较[J].中华临床医师杂志, 2012, 6(19):6049-6051. [2] 李洋. 匹伐他汀钙片治疗糖尿病合并高胆固醇血症的临床效果观察[J].中国医药指南, 2016, 14(5):126-127. [3] SATTAR N, PREISS D, MURRAY H M, et al. Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials[J].Lancet,2010, 375(9716):735-742. [4] FREEMAN D J, NORRIE J, SATTAR N, et al. Pravastatin and thedevelopment of diabetes mellitus:evidence for a protectivetreatment effect in the West of Scotland Coronary Prevention Study[J].Circulation,2001, 103(3):357-362. [5] STROES E S, THOMPSON P D, CORSINI A,et al. Statin-associated musclesymptoms:impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management[J].Eur Heart J,2015,36(17):1012-1022. [6] BAYS H,COHEN D E,CHALASANI N,et al. An assessment by the statinliver safety task force:2014 update[J].J Clin Lipidol,2014,8(Suppl 3):S47-S57. [7] RAVI V, SHAH M D, ALLISON B, et al. Statins and risk of new-onset diabetes mellitus[J].Circulation,2012, 126(18):e282-e284. [8] GOSHO M, TANAHASHI M, HOUNSLOW N, et al. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions:analysis of real-world and phase 3 clinical trial data[J].Int J Clin Pharm Th,2015, 53(8):635-646. [9] AOKI T, YAMAZAKI H, TAMAKI T, et al. Triglyceride-lowering effect of pitavastatin in guinea pigs model of postprandial lipemia[J].Arzneimittelforschung,2003, 53(3):154-158. [10] TOMOYA M, SHIHO N, HIROKO A,et al.Comparison of effects of pitavastatin and atorvastatin on glucose etabolism in type 2 diabetic patients with hypercholesterolemia[J].J Diabetes Investig,2013,4(3):297-303. [11] 吕兰兰, 刘雪龙. 匹伐他汀钙片的降糖效果及其治疗糖尿病高胆固醇血症的疗效[J].当代临床医刊, 2016, 29(5):2518. [12] 岳晨, 刘小利. 匹伐他汀钙片对血糖的效应及其治疗糖尿病高胆固醇血症的临床疗效[J].糖尿病新世界, 2016, 19(19):43-44. [13] 田静, 李影,刘芳. 匹伐他汀钙片对2型糖尿病模型大鼠肾脏损伤的保护机制[J].西北药物杂质, 2019,34(1):68-71.
2021, Vol. 38 
